The mechanisms of action of valproate in neuropsychiatric disorders: Can we see the forest for the trees?

Cellular and Molecular Life Sciences

Volumn 64, Issue 16, 2007, Pages 2090-2103

  Rosenberg, G ^a  

^a D Pharm Ltd   (Israel)

Author keywords

Antiepileptic; Bipolar disorder; Histone deacetylase; Migraine; Neuroprotection; Signal transduction; Valproate

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; ARACHIDONIC ACID; BETA CATENIN; CARBAMAZEPINE; CYTOSKELETON PROTEIN; DNA BINDING PROTEIN; ETIRACETAM; GLYCOGEN SYNTHASE KINASE 3; HISTONE DEACETYLASE; INOSITOL; LACTIC ACID; LITHIUM; MEVALONIC ACID; MITOGEN ACTIVATED PROTEIN KINASE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTAGLANDIN SYNTHASE INHIBITOR; PROTEIN KINASE C; SEROTONIN 2A RECEPTOR; SETOPERONE; TOPIRAMATE; TRANSCRIPTION FACTOR AP 1; VALPROIC ACID; WNT PROTEIN; ENZYME INHIBITOR; GABAERGIC RECEPTOR AFFECTING AGENT; PHOSPHATIDYLINOSITOL;

BIOCHEMISTRY; BIPOLAR DISORDER; CELL ACTIVITY; CELL SURVIVAL; CYTOSKELETON; DRUG MECHANISM; DRUG METABOLISM; EPILEPSY; FATTY ACID METABOLISM; GENE EXPRESSION; GENOMICS; HOMEOSTASIS; HUMAN; LIPID BRAIN LEVEL; MIGRAINE; MOOD DISORDER; MUTATION; NEUROPSYCHIATRY; NEUROTRANSMISSION; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROPHYLAXIS; PROTEIN MODIFICATION; REVIEW; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; ANIMAL; BRAIN; CHEMICAL STRUCTURE; CHEMISTRY; DRUG EFFECT; GENE EXPRESSION REGULATION; LIPID METABOLISM; METABOLISM;

ANIMALS; ANTICONVULSANTS; BETA CATENIN; BIPOLAR DISORDER; BRAIN; ENZYME INHIBITORS; EPILEPSY; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; GABA AGENTS; GENE EXPRESSION REGULATION; GLYCOGEN SYNTHASE KINASE 3; HUMANS; LIPID METABOLISM; MIGRAINE DISORDERS; MOLECULAR STRUCTURE; PHOSPHATIDYLINOSITOLS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; VALPROIC ACID; WNT PROTEINS;

EID: 35248894933     PISSN: 1420682X     EISSN: 15691632     Source Type: Journal    
DOI: 10.1007/s00018-007-7079-x     Document Type: Review

References (142)

1. Loescher, W. (2002) Valproic acid mechanisms of action. In: Antiepileptic Drugs, pp. 767-779, Levy, R. H., Mattson, R. H., Meldrum, B. S. and Perucca, E. (Eds)., Lippincott Williams & Wilkins, Philadelphia.
2. Fountoulakis, K. N., Vieta, E., Sanchez-Moreno, J., Kaprinis, S. G., Goikolea, J. M. and Kaprinis, G. S. (2005) Treatment guidelines for bipolar disorder: a critical review. J. Affect. Disord. 86, 1-10.
3. Bowden, C. L. (2003) Valproate. Bipolar Disord. 5, 189-202.
4. Chronicle, E. and Mulleners, W. (2004) Anticonvulsant drugs for migraine prophylaxis. Cochrane Database Syst. Rev. CD003226.
5. Johannessen, C. U. (2000) Mechanisms of action of valproate: a commentatory. Neurochem. Int. 37, 103-1110.
6. Rho, J. M. and Sankar, R. (1999) The pharmacologic basis of antiepileptic drug action. Epilepsia 40, 1471-1483.
7. Perucca, E. (2005) An introduction to antiepileptic drugs. Epilepsia 46 Suppl. 4, 31-37.
8. Freeman, M. P., Freeman, S. A. and McElroy, S. L. (2002) The comorbidity of bipolar and anxiety disorders: prevalence, psychobiology, and treatment issues. J. Affect. Disord. 68, 1-23.
9. Li, X., Ketter, T. A. and Frye, M. A. (2002) Synaptic, intracellular, and neuroprotective mechanisms of anticonvulsants: are they relevant for the treatment and course of bipolar disorders? J. Affect. Disord. 69, 1-14.
10. Manji, H. K., Moore, G. J. and Chen, G. (2001) Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers. Br. J. Psychiatry 178, S107-119.
11. Lee, W. S., Limmroth, V., Ayata, C., Cutrer, F. M., Waeber, C., Yu, X. and Moskowitz, M. A. (1995) Peripheral GABAA receptor-mediated effects of sodium valproate on dural plasma protein extravasation to substance P and trigeminal stimulation. Br. J. Pharmacol. 116, 1661-1667.
12. Ayata, C., Jin, H., Kudo, C., Dalkara, T. and Moskowitz, M. A. (2006) Suppression of cortical spreading depression in migraine prophylaxis. Ann. Neurol. 59, 652-661.
13. Porubek, D. J., Grillo, M. P. and Baillie, T. A. (1989) The covalent binding to protein of valproic acid and its hepatotoxic metabolite, 2-n-propyl-4-pentenoic acid, in rats and in isolated rat hepatocytes. Drug Metab. Dispos. 17, 123-130.
14. Rogawski, M. A. and Loscher, W. (2004) The neurobiology of antiepileptic drugs for the treatment of nonepileptic conditions. Nat. Med. 10, 685-692.
15. Lockard, J. S. and Levy, R. H. (1976) Valproic acid: reversibly acting drug? Epilepsia 17, 477-479.
16. Kultima, K., Nystrom, A. M., Scholz, B., Gustafson, A. L., Dencker, L. and Stigson, M. (2004) Valproic acid teratogenicity: a toxicogenomics approach. Environ. Health Perspect. 112, 1225-1235.
17. Eickholt, B. J., Towers, G. J., Ryves, W. J., Eikel, D., Adley, K., Ylinen, L. M., Chadborn, N. H., Harwood, A. J., Nau, H. and Williams, R. S. (2005) Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, glycogen synthase kinase-3beta inhibition, and viral replication: a screening approach for new bipolar disorder drugs derived from the valproic acid core structure. Mol. Pharmacol. 67, 1426-1433.
18. Phiel, C. J., Zhang, F., Huang, E. Y., Guenther, M. G., Lazar, M. A. and Klein, P. S. (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276, 36734-36741.
19. Plant, N., Barber, P., Horner, E., Cockburn, C. L., Gibson, G., Bugelski, P. and Lord, P. (2002) Differential gene expression in rats following subacute exposure to the anticonvulsant sodium valproate. Toxicol. Appl. Pharmacol. 183, 127-134.
20. Qiao, L., Schaack, J. and Shao, J. (2006) Suppression of adiponectin gene expression by histone deacetylase inhibitor valproic acid. Endocrinology 147, 865-874.
21. Chen, G. and Manji, H. K. (2006) The extracellular signal-regulated kinase pathway: an emerging promising target for mood stabilizers. Curr. Opin. Psychiatry 19, 313-323.
22. Einat, H., Yuan, P., Gould, T. D., Li, J., Du, J., Zhang, L., Manji, H. K. and Chen, G. (2003) The role of the extracellular signal-regulated kinase signaling pathway in mood modulation. J. Neurosci. 23, 7311-7316.
23. Yuan, P. X., Huang, L. D., Jiang, Y. M., Gutkind, J. S., Manji, H. K. and Chen, G. (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem. 276, 31674-31683.
24. Johnson, C. M., Hill, C. S., Chawla, S., Treisman, R. and Bading, H. (1997) Calcium controls gene expression via three distinct pathways that can function independently of the Ras/mitogen-activated protein kinases (ERKs) signaling cascade. J. Neurosci. 17, 6189-6202.
25. Chen, G., Zeng, W. Z., Yuan, P. X., Huang, L. D., Jiang, Y. M., Zhao, Z. H. and Manji, H. K. (1999) The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J. Neurochem. 72, 879-882.
26. Hao, Y., Creson, T., Zhang, L., Li, P., Du, F., Yuan, P., Gould, T. D., Manji, H. K. and Chen, G. (2004) Mood stabilizer valproate promotes ERK pathway-dependent cortical neuronal growth and neurogenesis. J. Neurosci. 24, 6590-6599.
27. Fukumoto, T., Morinobu, S., Okamoto, Y., Kagaya, A. and Yamawaki, S. (2001) Chronic lithium treatment increases the expression of brain-derived neurotrophic factor in the rat brain. Psychopharmacology (Berl.) 158, 100-106.
28. Jansen, M. S., Nagel, S. C., Miranda, P. J., Lobenhofer, E. K., Afshari, C. A. and McDonnell, D. P. (2004) Short-chain fatty acids enhance nuclear receptor activity through mitogen-activated protein kinase activation and histone deacetylase inhibition. Proc. Natl. Acad. Sci. USA 101, 7199-7204.
29. Harrison, P. J. (2002) The neuropathology of primary mood disorder. Brain 125, 1428-1449.
30. Monkul, E. S., Malhi, G. S. and Soares, J. C. (2005) Anatomical MRI abnormalities in bipolar disorder: do they exist and do they progress? Aust. NZ J. Psychiatry 39, 222-226.
31. Moore, G. J., Bebchuk, J. M., Wilds, I. B., Chen, G. and Manji, H. K. (2000) Lithium-induced increase in human brain grey matter. Lancet 356, 1241-1242.
32. Pliszka, S. R., Lancaster, J., Liotti, M. and Semrud-Clikeman, M. (2006) Volumetric MRI differences in treatment-naive vs chronically treated children with ADHD. Neurology 67, 1023-1027.
33. Weiss, S. R. and Post, R. M. (1998) Kindling: separate vs. shared mechanisms in affective disorders and epilepsy. Neuropsychobiology 38, 167-180.
34. Cendes, F. (2005) Progressive hippocampal and extrahippocampal atrophy in drug resistant epilepsy. Curr. Opin. Neurol. 18, 173-177.
35. Laeng, P., Pitts, R. L., Lemire, A. L., Drabik, C. E., Weiner, A., Tang, H., Thyagarajan, R., Mallon, B. S. and Altar, C. A. (2004) The mood stabilizer valproic acid stimulates GABA neurogenesis from rat forebrain stem cells. J. Neurochem. 91, 238-251.
36. Koyama, R. and Ikegaya, Y. (2005) To BDNF or not to BDNF: that is the epileptic hippocampus. Neuroscientist 11, 282-287.
37. Yamada, M. K., Nakanishi, K., Ohba, S., Nakamura, T., Ikegaya, Y., Nishiyama, N. and Matsuki, N. (2002) Brain-derived neurotrophic factor promotes the maturation of GABAergic mechanisms in cultured hippocampal neurons. J. Neurosci. 22, 7580-7585.
38. Huntsman, M. M., Porcello, D. M., Homanics, G. E., DeLorey, T. M. and Huguenard, J. R. (1999) Reciprocal inhibitory connections and network synchrony in the mammalian thalamus. Science 283, 541-543.
39. Hsieh, J., Nakashima, K., Kuwabara, T., Mejia, E. and Gage, F. H. (2004) Histone deacetylase inhibition-mediated neuronal differentiation of multipotent adult neural progenitor cells. Proc. Natl. Acad. Sci. USA 101, 16659-16664.
40. Siafaka-Kapadai, A., Patiris, M., Bowden, C. and Javors, M. (1998) Incorporation of [3H]valproic acid into lipids in GT1-7 neurons. Biochem. Pharmacol. 56, 207-212.
41. Bassa, B. V., Roh, D. D., Vaziri, N. D., Kirschenbaum, M. A. and Kamanna, V. S. (1999) Lysophosphatidylcholine activates mesangial cell PKC and MAP kinase by PLCgamma-1 and tyrosine kinase-Ras pathways. Am. J. Physiol. 277, F328-337.
42. Bazinet, R. P., Weis, M. T., Rapoport, S. I. and Rosenberger, T. A. (2006) Valproic acid selectively inhibits conversion of arachidonic acid to arachidonoyl-CoA by brain microsomal long-chain fatty acyl-CoA synthetases: relevance to bipolar disorder. Psychopharmacology (Berl.) 184, 122-129.
43. Silverstone, P. H., McGrath, B. M. and Kim, H. (2005) Bipolar disorder and myo-inositol: a review of the magnetic resonance spectroscopy findings. Bipolar Disord. 7, 1-10.
44. Shaltiel, G., Shamir, A., Shapiro, J., Ding, D., Dalton, E., Bialer, M., Harwood, A. J., Belmaker, R. H., Greenberg, M. L. and Agam, G. (2004) Valproate decreases inositol biosynthesis. Biol. Psychiatry 56, 868-874.
45. Ju, S., Shaltiel, G., Shamir, A., Agam, G. and Greenberg, M. L. (2004) Human 1-D-myo-inositol-3-phosphate synthase is functional in yeast. J. Biol. Chem. 279, 21759-21765.
46. Einat, H., Chen, G. and Manji, H. (2004) [Possible involvement of protein kinase C in the pathophysiology and treatment of bipolar disorder]. Harefuah 143, 420-425, 462.
47. Harwood, A. J. (2005) Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited. Mol. Psychiatry 10, 117-126.
48. Hahn, C. G., Umapathy, Wang, H. Y., Koneru, R., Levinson, D. F. and Friedman, E. (2005) Lithium and valproic acid treatments reduce PKC activation and receptor-G protein coupling in platelets of bipolar manic patients. J. Psychiatr. Res. 39, 355-363.
49. Wang, H. Y. and Friedman, E. (1996) Enhanced protein kinase C activity and translocation in bipolar affective disorder brains. Biol. Psychiatry 40, 568-575.
50. Wang, H. Y., Markowitz, P., Levinson, D., Undie, A. S. and Friedman, E. (1999) Increased membrane-associated protein kinase C activity and translocation in blood platelets from bipolar affective disorder patients. J. Psychiatr. Res. 33, 171-179.
51. Wang, H. and Friedman, E. (2001) Increased association of brain protein kinase C with the receptor for activated C kinase-1 (RACK1) in bipolar affective disorder. Biol. Psychiatry 50, 364-370.
52. Manji, H. K., Etcheberrigaray, R., Chen, G. and Olds, J. L. (1993) Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J. Neurochem. 61, 2303-2310.
53. Toth, M. (2005) The epsilon theory: a novel synthesis of the underlying molecular and electrophysiological mechanisms of primary generalized epilepsy and the possible mechanism of action of valproate. Med. Hypotheses 64, 267-272.
54. Guglielmetti, F., Rattray, M., Baldessari, S., Butelli, E., Samanin, R. and Bendotti, C. (1997) Selective up-regulation of protein kinase C epsilon in granule cells after kainic acid-induced seizures in rat. Brain Res. Mol. Brain Res. 49, 188-196.
55. Hodge, C. W., Mehmert, K. K., Kelley, S. P., McMahon, T., Haywood, A., Olive, M. F., Wang, D., Sanchez-Perez, A. M. and Messing, R. O. (1999) Supersensitivity to allosteric GABA(A) receptor modulators and alcohol in mice lacking PKC-epsilon. Nat. Neurosci. 2, 997-1002.
56. Chen, G., Manji, H. K., Hawver, D. B., Wright, C. B. and Potter, W. Z. (1994) Chronic sodium valproate selectively decreases protein kinase C alpha and epsilon in vitro. J. Neurochem. 63, 2361-2364.
57. Williams, R. S., Cheng, L., Mudge, A. W. and Harwood, A. J. (2002) A common mechanism of action for three mood-stabilizing drugs. Nature 417, 292-295.
58. Watterson, J. M., Watson, D. G., Meyer, E. M. and Lenox, R. H. (2002) A role for protein kinase C and its substrates in the action of valproic acid in the brain: implications for neural plasticity. Brain Res. 934, 69-80.
59. Watson, D. G., Watterson, J. M. and Lenox, R. H. (1998) Sodium valproate down-regulates the myristoylated alanine-rich C kinase substrate (MARCKS) in immortalized hippocampal cells: a property of protein kinase C-mediated mood stabilizers. J. Pharmacol. Exp. Ther. 285, 307-316.
60. McNamara, R. K., Stumpo, D. J., Morel, L. M., Lewis, M. H., Wakeland, E. K., Blackshear, P. J. and Lenox, R. H. (1998) Effect of reduced myristoylated alanine-rich C kinase substrate expression on hippocampal mossy fiber development and spatial learning in mutant mice: transgenic rescue and interactions with gene background. Proc. Natl. Acad. Sci. USA 95, 14517-14522.
61. Junoy, B., Maccario, H., Mas, J. L., Enjalbert, A. and Drouva, S. V. (2002) Proteasome implication in phorbol ester- and GnRH-induced selective down-regulation of PKC (alpha, epsilon, zeta) in alpha T(3)-1 and L beta T(2) gonadotrope cell lines. Endocrinology 143, 1386-1403.
62. Zgouras, D., Becker, U., Loitsch, S. and Stein, J. (2004) Modulation of angiogenesis-related protein synthesis by valproic acid. Biochem. Biophys. Res. Commun. 316, 693-697.
63. Blaheta, R. A. and Cinatl, J., Jr. (2002) Anti-tumor mechanisms of valproate: a novel role for an old drug. Med. Res. Rev. 22, 492-511.
64. Doble, B. W. and Woodgett, J. R. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci. 116, 1175-1186.
65. Hetman, M., Cavanaugh, J. E., Kimelman, D. and Xia, Z. (2000) Role of glycogen synthase kinase-3beta in neuronal apoptosis induced by trophic withdrawal. J. Neurosci. 20, 2567-2574.
66. Chen, G., Huang, L. D., Jiang, Y. M. and Manji, H. K. (1999) The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem. 72, 1327-1330.
67. Grimes, C. A. and Jope, R. S. (2001) CREB DNA binding activity is inhibited by glycogen synthase kinase-3 beta and facilitated by lithium. J. Neurochem. 78, 1219-1232.
68. Kim, A. J., Shi, Y., Austin, R. C. and Werstuck, G. H. (2005) Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell Sci. 118, 89-99.
69. Hall, A. C., Brennan, A., Goold, R. G., Cleverley, K., Lucas, F. R., Gordon-Weeks, P. R. and Salinas, P. C. (2002) Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci. 20, 257-270.
70. Ryves, W. J., Dalton, E. C., Harwood, A. J. and Williams, R. S. (2005) GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord. 7, 260-265.
71. Tatebayashi, Y., Haque, N., Tung, Y. C., Iqbal, K. and Grundke-Iqbal, I. (2004) Role of tau phosphorylation by glycogen synthase kinase-3beta in the regulation of organelle transport. J. Cell Sci. 117, 1653-1663.
72. Jin, N., Kovacs, A. D., Sui, Z., Dewhurst, S. and Maggirwar, S. B. (2005) Opposite effects of lithium and valproic acid on trophic factor deprivation-induced glycogen synthase kinase-3 activation, c-Jun expression and neuronal cell death. Neuropharmacology 48, 576-583.
73. De Sarno, P., Li, X. and Jope, R. S. (2002) Regulation of Akt and glycogen synthase kinase-3 beta phosphorylation by sodium valproate and lithium. Neuropharmacology 43, 1158-1164.
74. Kozlovsky, N., Nadri, C., Belmaker, R. H. and Agam, G. (2003) Lack of effect of mood stabilizers or neuroleptics on GSK-3 protein levels and GSK-3 activity. Int. J. Neuropsychopharmacol. 6, 117-120.
75. Kozlovsky, N., Amar, S., Belmaker, R. H. and Agam, G. (2006) Psychotropic drugs affect Ser9-phosphorylated GSK-3 beta protein levels in rodent frontal cortex. Int. J. Neuropsychopharmacol. 9, 337-342.
76. Roh, M. S., Eom, T. Y., Zmijewska, A. A., De Sarno, P., Roth, K. A. and Jope, R. S. (2005) Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol. Psychiatry 57, 278-286.
77. Gould, T. D., Chen, G. and Manji, H. K. (2004) In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology 29, 32-38.
78. Agam, G., Shaltiel, G., Kozlovsky, N., Shimon, H. and Belmaker, R. H. (2003) Lithium inhibitable enzymes in postmortem brain of bipolar patients. J. Psychiatr. Res. 37, 433-442.
79. Beasley, C., Cotter, D. and Everall, I. (2002) An investigation of the Wnt-signalling pathway in the prefrontal cortex in schizophrenia, bipolar disorder and major depressive disorder. Schizophr. Res. 58, 63-67.
80. Lesort, M., Greendorfer, A., Stockmeier, C., Johnson, G. V. and Jope, R. S. (1999) Glycogen synthase kinase-3beta, beta-catenin, and tau in postmortem bipolar brain. J. Neural. Transm. 106, 1217-1222.
81. Deutsch, J., Rapoport, S. I. and Rosenberger, T. A. (2003) Valproyl-CoA and esterified valproic acid are not found in brains of rats treated with valproic acid, but the brain concentrations of CoA and acetyl-CoA are altered. Neurochem. Res. 28, 861-866.
82. Bolanos, J. P. and Medina, J. M. (1997) Effect of valproate on the metabolism of the central nervous system. Life Sci. 60, 1933-1942
83. Finch, C. and Roth, G. (1998) Biochemistry of aging. In: Basic Neurochemistry: Molecular, Cellular and Medical Aspects, pp. 613-635, Siegel, G., Agranoff, B., Albers, R., Fisher, S. and Uhler, M. (Eds). Lippincott Williams & Wilkins, Philadelphia.
84. Choi, J. H. and Yu, B. P. (1995) Brain synaptosomal aging: free radicals and membrane fluidity. Free Radic. Biol. Med. 18, 133-139.
85. +. Eur. J. Biochem. 266, 886-891.
86. Chang, M. C., Contreras, M. A., Rosenberger, T. A., Rintala, J. J., Bell, J. M. and Rapoport, S. I. (2001) Chronic valproate treatment decreases the in vivo turnover of arachidonic acid in brain phospholipids: a possible common effect of mood stabilizers. J. Neurochem. 77, 796-803.
87. Bosetti, F., Weerasinghe, G. R., Rosenberger, T. A. and Rapoport, S. I. (2003) Valproic acid down-regulates the conversion of arachidonic acid to eicosanoids via cyclooxygenase-1 and -2 in rat brain. J. Neurochem. 85, 690-696.
88. Rapoport, S. I. and Bosetti, F. (2002) Do lithium and anticonvulsants target the brain arachidonic acid cascade in bipolar disorder? Arch. Gen. Psychiatry 59, 592-596.
89. Stoll, A. L., Severus, W. E., Freeman, M. P., Rueter, S., Zboyan, H. A., Diamond, E., Cress, K. K. and Marangell, L. B. (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch. Gen. Psychiatry 56, 407-412.
90. Sublette, M. E., Russ, M. J. and Smith, G. S. (2004) Evidence for a role of the arachidonic acid cascade in affective disorders: a review. Bipolar Disord. 6, 95-105.
91. Maida, M. E., Hurley, S. D., Daeschner, J. A., Moore, A. H. and O'Banion, M. K. (2006) Cytosolic prostaglandin E2 synthase (cPGES) expression is decreased in discrete cortical regions in psychiatric disease. Brain Res. 1103, 164-172.
92. Cole-Edwards, K. K. and Bazan, N. G. (2005) Lipid signaling in experimental epilepsy. Neurochem. Res. 30, 847-853.
93. Phillis, J. W., Horrocks, L. A. and Farooqui, A. A. (2006) Cyclooxygenases, lipoxygenases, and epoxygenases in CNS: their role and involvement in neurological disorders. Brain Res. Brain Res. Rev 52, 201-243.
94. Snow, V., Weiss, K., Wall, E. M. and Mottur-Pilson, C. (2002) Pharmacologic management of acute attacks of migraine and prevention of migraine headache. Ann. Intern. Med. 137, 840-849.
95. Davis, R. J., Murdoch, C. E., Ali, M., Purbrick, S., Ravid, R., Baxter, G. S., Tilford, N., Sheldrick, R. L., Clark, K. L. and Coleman, R. A. (2004) EP4 prostanoid receptor-mediated vasodilatation of human middle cerebral arteries. Br. J. Pharmacol. 141, 580-585.
96. Sullivan, N. R., Burke, T., Siafaka-Kapadai, A., Javors, M. and Hensler, J. G. (2004) Effect of valproic acid on serotonin-2A receptor signaling in C6 glioma cells. J. Neurochem. 90, 1269-1275.
97. Rothrock, J. F. and Mendizabal, J. E. (2000) An analysis of the "carry-over effect" following successful short-term treatment of transformed migraine with divalproex sodium. Headache 40, 17-19.
98. Wassef, A. A., Dott, S. G., Harris, A., Brown, A., O'Boyle, M., Meyer, W. J., 3rd and Rose, R. M. (2000) Randomized, placebo-controlled pilot study of divalproex sodium in the treatment of acute exacerbations of chronic schizophrenia. J. Clin. Psychopharmacol. 20, 357-361.
99. Rowan, A. J., Binnie, C. D., Warfield, C. A., Meinardi, H. and Meijer, J. W. (1979) The delayed effect of sodium valproate on the photoconvulsive response in man. Epilepsia 20, 61-68.
100. Serdaroglu, G., Erhan, E., Tekgul, H., Oksel, F., Erermis, S., Uyar, M. and Tutuncuoglu, S. (2002) Sodium valproate prophylaxis in childhood migraine. Headache 42, 819-822.
101. Silberstein, S. D. and Collins, S. D. (1999) Safety of divalproex sodium in migraine prophylaxis: an open-label, long-term study. Long-term Safety of Depakote in Headache Prophylaxis Study Group. Headache 39, 633-643.
102. Loscher, W., Fisher, J. E., Nau, H. and Honack, D. (1988) Marked increase in anticonvulsant activity but decrease in wet-dog shake behaviour during short-term treatment of amygdala-kindled rats with valproic acid. Eur. J. Pharmacol. 150, 221-232.
103. Lopez-Figueroa, A. L., Norton, C. S., Lopez-Figueroa, M. O., Armellini-Dodel, D., Burke, S., Akil, H., Lopez, J. F. and Watson, S. J. (2004) Serotonin 5-HT1A, 5-HT1B, and 5-HT2A receptor mRNA expression in subjects with major depression, bipolar disorder, and schizophrenia. Biol. Psychiatry 55, 225-233.
104. Dean, B., Pavey, G., McLeod, M., Opeskin, K., Keks, N. and Copolov, D. (2001) A change in the density of [(3)H]flumazenil, but not [(3)H]muscimol binding, in Brodmann's area 9 from subjects with bipolar disorder. J. Affect. Disord. 66, 147-158.
105. Yatham, L. N., Liddle, P. F., Lam, R. W., Adam, M. J., Solomons, K., Chinnapalli, M. and Ruth, T. J. (2005) A positron emission tomography study of the effects of treatment with valproate on brain 5-HT2A receptors in acute mania. Bipolar Disord. 7 Suppl 5, 53-57.
106. Sands, S. A., Guerra, V. and Morilak, D. A. (2000) Changes in tyrosine hydroxylase mRNA expression in the rat locus coeruleus following acute or chronic treatment with valproic acid. Neuropsychopharmacology 22, 27-35.
107. Chen, B., Wang, J. F. and Young, L. T. (2000) Chronic valproate treatment increases expression of endoplasmic reticulum stress proteins in the rat cerebral cortex and hippocampus. Biol. Psychiatry 48, 658-664.
108. Bosetti, F., Bell, J. M. and Manickam, P. (2005) Microarray analysis of rat brain gene expression after chronic administration of sodium valproate. Brain Res. Bull. 65, 331-338.
109. Tang, Y., Glauser, T. A., Gilbert, D. L., Hershey, A. D., Privitera, M. D., Ficker, D. M., Szaflarski, J. P. and Sharp, F. R. (2004) Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study. Acta Neurol. Scand. 109, 159-168.
110. Herdegen, T. and Waetzig, V. (2001) AP-1 proteins in the adult brain: facts and fiction about effectors of neuroprotection and neurodegeneration. Oncogene 20, 2424-2437.
111. Hughes, P. and Dragunow, M. (1995) Induction of immediate-early genes and the control of neurotransmitter-regulated gene expression within the nervous system. Pharmacol. Rev. 47, 133-178.
112. Chen, G., Yuan, P., Hawver, D. B., Potter, W. Z. and Manji, H. K. (1997) Increase in AP-1 transcription factor DNA binding activity by valproic acid. Neuropsychopharmacology 16, 238-245.
113. Chen, G., Yuan, P. X., Jiang, Y. M., Huang, L. D. and Manji, H. K. (1999) Valproate robustly enhances AP-1 mediated gene expression. Brain Res. Mol. Brain Res. 64, 52-58.
114. Asghari, V., Wang, J. F., Reiach, J. S. and Young, L. T. (1998) Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res. Mol. Brain Res. 58, 95-102.
115. Chen, B., Wang, J. F., Hill, B. C. and Young, L. T. (1999) Lithium and valproate differentially regulate brain regional expression of phosphorylated CREB and c-Fos. Brain Res. Mol. Brain Res. 70, 45-53.
116. Szot, P., White, S. S., Shen, D. D. and Anderson, G. D. (2005) Valproic acid, but not lamotrigine, suppresses seizure-induced c-fos and c-Jun mRNA expression. Brain Res. Mol. Brain Res. 135, 285-289.
117. Arinze, I. J. and Kawai, Y. (2003) Sp family of transcription factors is involved in valproic acid-induced expression of Galphai2. J. Biol. Chem. 278, 17785-17791.
118. Newton, S. S. and Duman, R. S. (2006) Chromatin remodeling: a novel mechanism of psychotropic drug action. Mol. Pharmacol. 70, 440-443.
119. Acharya, M. R., Sparreboom, A., Venitz, J. and Figg, W. D. (2005) Rational development of histone deacetylase inhibitors as anticancer agents: a review. Mol. Pharmacol. 68, 917-932.
120. Van Lint, C., Emiliani, S. and Verdin, E. (1996) The expression of a small fraction of cellular genes is changed in response to histone hyperacetylation. Gene Expr. 5, 245-253.
121. Eyal, S., Yagen, B., Shimshoni, J. and Bialer, M. (2005) Histone deacetylases inhibition and tumor cells cytotoxicity by CNS-active VPA constitutional isomers and derivatives. Biochem. Pharmacol. 69, 1501-1508.
122. Eyal, S., Yagen, B., Sobol, E., Altschuler, Y., Shmuel, M. and Bialer, M. (2004) The activity of antiepileptic drugs as histone deacetylase inhibitors. Epilepsia 45, 737-744.
123. Yildirim, E., Zhang, Z., Uz, T., Chen, C. Q., Manev, R. and Manev, H. (2003) Valproate administration to mice increases histone acetylation and 5-lipoxygenase content in the hippocampus. Neurosci. Lett. 345, 141-143.
124. Sharma, R. P., Rosen, C., Kartan, S., Guidotti, A., Costa, E., Grayson, D. R. and Chase, K. (2006) Valproic acid and chromatin remodeling in schizophrenia and bipolar disorder: Preliminary results from a clinical population. Schizophr. Res. 88, 227-231.
125. Huang, Y., Doherty, J. J. and Dingledine, R. (2002) Altered histone acetylation at glutamate receptor 2 and brain-derived neurotrophic factor genes is an early event triggered by status epilepticus. J. Neurosci. 22, 8422-8428.
126. Tsankova, N. M., Kumar, A. and Nestler, E. J. (2004) Histone modifications at gene promoter regions in rat hippocampus after acute and chronic electroconvulsive seizures. J. Neurosci. 24, 5603-5610.
127. Han, B. H. and Holtzman, D. M. (2000) BDNF protects the neonatal brain from hypoxic-ischemic injury in vivo via the ERK pathway. J. Neurosci. 20, 5775-5781.
128. Michaelis, M., Suhan, T., Michaelis, U. R., Beek, K., Rothweiler, F., Tausch, L., Werz, O., Eikel, D., Zornig, M., Nau, H., Fleming, I., Doerr, H. W. and Cinatl, J., Jr. (2006) Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells. Cell Death Differ. 13, 446-453.
129. Yamaguchi, K., Lantowski, A., Dannenberg, A. J. and Subbaramaiah, K. (2005) Histone deacetylase inhibitors suppress the induction of c-Jun and its target genes including COX-2. J. Biol. Chem. 280, 32569-32577.
130. Rickard, K. L., Gibson, P. R., Wilson, N. J., Mariadason, J. M. and Phillips, W. A. (2000) Short-chain fatty acids reduce expression of specific protein kinase C isoforms in human colonic epithelial cells. J. Cell Physiol. 182, 222-231.
131. Honack, D. and Loscher, W. (1992) Intravenous valproate: onset and duration of anticonvulsant activity against a series of electroconvulsions in comparison with diazepam and phenytoin. Epilepsy Res. 13, 215-221.
132. Grooms, S. Y., Opitz, T., Bennett, M. V. and Zukin, R. S. (2000) Status epilepticus decreases glutamate receptor 2 mRNA and protein expression in hippocampal pyramidal cells before neuronal death. Proc. Natl. Acad. Sci. USA 97, 3631-3636.
133. Du, J., Suzuki, K., Wei, Y., Wang, Y., Blumenthal, R., Chen, Z., Falke, C., Zarate, C. A., Jr. and Manji, H. K. (2007) The anticonvulsants lamotrigine, riluzole, and valproate differentially regulate AMPA receptor membrane localization: relationship to clinical effects in mood disorders. Neuropsychopharmacology 32, 793-802.
134. Ren, M., Leng, Y., Jeong, M., Leeds, P. R. and Chuang, D. M. (2004) Valproic acid reduces brain damage induced by transient focal cerebral ischemia in rats: potential roles of histone deacetylase inhibition and heat shock protein induction. J. Neurochem. 89, 1358-1367.
135. Ichiyama, T., Okada, K., Lipton, J. M., Matsubara, T., Hayashi, T. and Furukawa, S. (2000) Sodium valproate inhibits production of TNF-alpha and IL-6 and activation of NF-kappaB. Brain Res. 857, 246-251.
136. Peng, G. S., Li, G., Tzeng, N. S., Chen, P. S., Chuang, D. M., Hsu, Y. D., Yang, S. and Hong, J. S. (2005) Valproate pretreatment protects dopaminergic neurons from LPS-induced neurotoxicity in rat primary midbrain cultures: role of microglia. Brain Res. Mol. Brain Res. 134, 162-169.
137. Maes, M., Bosmans, E., Calabrese, J., Smith, R. and Meltzer, H. Y. (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J. Psychiatr. Res. 29, 141-152.
138. Brandt, C., Gastens, A. M., Sun, M., Hausknecht, M. and Loscher, W. (2006) Treatment with valproate after status epilepticus: effect on neuronal damage, epileptogenesis, and behavioral alterations in rats. Neuropharmacology 51, 789-804.
139. Kanai, H., Sawa, A., Chen, R. W., Leeds, P. and Chuang, D. M. (2004) Valproic acid inhibits histone deacetylase activity and suppresses excitotoxicity-induced GAPDH nuclear accumulation and apoptotic death in neurons. Pharmacogenom. J. 4, 336-344.
140. Sng, J. C., Taniura, H. and Yoneda, Y. (2006) Histone modifications in kainate-induced status epilepticus. Eur. J. Neurosci. 23, 1269-1282.
141. Beutler, A. S., Li, S., Nicol, R. and Walsh, M. J. (2005) Carbamazepine is an inhibitor of histone deacetylases. Life Sci. 76, 3107-3115.
142. Gottlicher, M., Minucci, S., Zhu, P., Kramer, O. H., Schimpf, A., Giavara, S., Sleeman, J. P., Lo Coco, F., Nervi, C., Pelicci, P. G. and Heinzel, T. (2001) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. Embo, J. 20, 6969-6978.